Drugs Made in America AcquisDMAAU
13F holders, Q2 2026 (June 30)2holders
0new positions
0sold out
$10.61avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Drugs Made in America Acquis (DMAAU) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Clear Street Group Inc. ($106K) and UBS Group AG ($16K).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2847J120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 9 shares bought, net +9 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Clear Street Group Inc. | 0.00% | Add +0.1% | 10,005 | $106K |
| UBS Group AG | 0.00% | Add +0.3% | 1,525 | $16K |
"% of holder's portfolio" is DMAAU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.